Exercise and zoledronic acid on lipid profile and bone remodeling in ovariectomized rats: A paradoxical negative association?

Lipids

Volumn 45, Issue 4, 2010, Pages 337-344

  Lespessailles, E ^a   Jaffr C ^a   Rochefort, G Y ^a   Dollans E ^a   Benhamou, C L ^a   Ourteix, D ^a  

^a CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

Author keywords

Atherosclerosis; Lipid metabolism

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; BONE REMODELING; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; INTERMETHOD COMPARISON; NONHUMAN; OSTEOLYSIS; OUTCOME ASSESSMENT; OVARIECTOMY; RAT; RISK REDUCTION; SINGLE DRUG DOSE; SITTING; TREADMILL EXERCISE;

ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; FEMALE; IMIDAZOLES; LIPID METABOLISM; LIPIDS; OVARIECTOMY; PHYSICAL CONDITIONING, ANIMAL; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 77953287276     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-010-3399-y     Document Type: Article

References (36)

1. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026
2. Fleisch H (1998) Bisphosphonates: Mechanisms of action. Endocr Rev 19:80-100
3. Buhaescu I, Izzedine H (2007) Mevalonate pathway: A review of clinical and therapeutical implications. Clin Biochem 40:575-584
4. Ciosek CP Jr, Magnin DR, Harrity TW, Logan JV, Dickson JK Jr, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM et al (1993) Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 268:24832-24837
5. Gozzetti A, Gennari L, Merlotti D, Salvadori S, De Paola V, Avanzati A, Franci B, Marchini E, Tozzi M, Campagna MS, Nuti R, Lauria F, Martini G (2008) The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif Tissue Int 82:258-262
6. Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper HC, Wells G, Tugwell P, Cranney A (2002) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev CD000333
7. Kelley GA, Kelley KS (2008) Efficacy of aerobic exercise on coronary heart disease risk factors. Prev Cardiol 11:71-75
8. Kelley GA, Kelley KS, Tran ZV (2005) Walking and non-HDL-C in adults: A meta-analysis of randomized controlled trials. Prev Cardiol 8:102-107
9. Vasankari TJ, Kujala UM, Vasankari TM, Ahotupa M (1998) Reduced oxidized LDL levels after a 10-month EX program. Med Sci Sports Exerc 30:1496-1501
10. Puglisi MJ, Vaishnav U, Shrestha S, Torres-Gonzalez M, Wood RJ, Volek JS, Fernandez ML (2008) Raisins and additional walking have distinct effects on plasma lipids and inflammatory cytokines. Lipids Health Dis 7:14
11. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28:465-473
12. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476
13. Boppart MD, Kimmel DB, Yee JA, Cullen DM (1998) Time course of osteoblast appearance after in vivo mechanical loading. Bone 23:409-415
14. Pead MJ, Skerry TM, Lanyon LE (1988) Direct transformation from quiescence to bone formation in the adult periosteum following a single brief period of bone loading. J Bone Miner Res 3:647-656
15. Skerry TM, Bitensky L, Chayen J, Lanyon LE (1989) Early strain-related changes in enzyme activity in osteocytes following bone loading in vivo. J Bone Miner Res 4:783-788
16. Wronski TJ, Schenck PA, Cintron M, Walsh CC (1987) Effect of body weight on osteopenia in ovariectomized rats. Calcif Tissue Int 40:155-159
17. Gasser JA, Green JR, Novartis Pharma AG (2002) Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats. Bone 30:41S
18. Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG (1993) Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 3:255-260
19. Neter J, Wasserman W, Ahitmore GA (1982) Applied statistics, 4 sub edn. Allyn & Bacon, Boston
20. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S (1996) Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 18:621-627
21. Ferreri LF, Naito HK (1978) Effect of estrogens on rat serum cholesterol concentration: Consideration of dose, type of estrogens and treatment duration. Endocrinology 102:1621-1627
22. Brown MS, Glodstein JL (1980) The estradiol stimulated lipoprotein receptor of rat liver. J Biol Chem 254:10454-10471
23. Chao Y, Windler EE, Chen GC, Havel RJ (1979) Hepatic catabolism of rat and human lipoproteins in rats treated with 17 alpha-ethinyl-estradiol. J Biol Chem 254:11360-11366
24. Kemmler W, Lauber D, Weineck J, Hensen J, Kalender W, Engelke K (2004) Benefits of 2 years of intense EX on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women: Results of the Erlangen Fitness Osteoporosis Prevention Study (EFOPS). Arch Intern Med 164:1084-1091
25. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E (2000) Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases lowdensity lipoprotein cholesterol. J Bone Miner Res 15:599-604
26. Guney E, Kisakol G, Ozgen AG, Yilmaz C, Kabalak T (2008) Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 29:252-255
27. Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C (2003) Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 32:15-19
28. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663
29. Tobert JA (1987) New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76:534-538
30. Thune I, Njolstad I, Lochen ML, Forde OH (1998) Physical activity improves the metabolic risk profiles in men and women: The Tromso Study. Arch Intern Med 158:1633-1640
31. Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386-392
32. Pedersen DK (2006) The anti-inflammatory effect of exercise: Its role in diabetes and cardio-vascular disease control. Essays Biochem 42:105-117
33. Corrado A, Santoro N, Cantatore FP (2007) Extra-skeletal effects of bisphosphonates. Joint Bone Spine 74:32-38
34. Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, Monkkonen J (1999) Contrasting effects of alendronate and clodronate on RAW 264 macrophages: The role of a bisphosphonate metabolite. Eur J Pharm Sci 8:109-118
35. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
36. Fuchs RK, Shea M, Durski SL, Winters-Stone KM, Widrick J, Snow CM (2007) Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone 41:290-296